Last week, an FDA advisory committee voted 21-0, with one abstention, to recommend granting emergency use authorization to Novavax’s two-dose COVID-19 vaccine for adults.

The vote came more than 4 months after Novavax asked the FDA to consider the protein-based vaccine for authorization. It was the top story in infectious disease last week.

Another top story covered Moderna’s bivalent COVID-19 vaccine booster candidate. According to a press release from the company, the booster elicited a superior antibody response against the omicron variant of SARS-CoV-2 compared with the original vaccine.

Read the top stories in infectious disease below:

FDA committee recommends EUA for Novavax’s COVID-19 vaccine

The Vaccines and Related Biological Products Advisory Committee recommended that Novavax’s COVID-19 vaccine be made available in the United States under an emergency use authorization.